Navigation Links
Aida Granted Additional Anti-Cancer Patent
Date:10/11/2007

SANTA MONICA, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA), one of mainland China's leading pharmaceutical companies, today announced that it was granted an additional patent related to its Rh-Apo2L anti-cancer drug, the second of three patents that had been applied for which Aida believes places it at the vanguard of China's pharmaceutical industry. The patent was jointly granted by China's State Intellectual Property Office ("SIPO") to East China University of Science& Technology ("ECUST") and Aida's majority-controlled subsidiary, Shanghai Quiaer Biotechnology Company, Ltd ("Shanghai Qiaer"). ECUST is the partner with Aida in the research of this field.

The patent, certificate number: 200510028037.6, deals with the cultivation of Rh-Apo2L. The main content of the patent includes the following:

-- the fermentative process dividing into five stages,

-- the different stage separately increasing the different C/N culture

medium,

-- realization of C and N demand balance, and

-- that the methodology set by Aida can effectively enhance the soluble

protein expression quantity while simultaneously reducing the

fermentative process of the ethanoic acid accumulation.

Mr. Jinsong Zhou, the CEO of Shanghai Qiaer stated, "This continues to establish Aida as a technology leader in not only the Chinese pharmaceutical field, but also in the international arena. Our scientists and researchers are deeply encouraged by the news and will reinforce our confidence in the ongoing clinical trials of Rh-Apo2L."

About Rh-Apo2L -- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. Rh-Apo2L has completed the Phase I clinical trials successfully in July 2006. This biopharmaceutical drug has gained the attention of researchers and clinical professionals throughout China who are observing the drug for potential replacement of surgery and radiation therapy for cancer. Potentially, over 8 million people can be treated each year in China with this drug.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.


'/>"/>
SOURCE Aida Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indian Doctor granted US patent on organ regeneration
2. Bail Granted To The Doctor Despite Her Patients Death
3. Azerbaijan Granted 5 million dollars in Fight Against Bird Flu
4. Developer Of Vaccine For Cancer Granted A Prestigious Fellowship
5. Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs
6. American Senior Citizens Granted More Time
7. Numerous Defense Personnel Granted Early Retirement Due to Mental Illness
8. Man Accused of Spreading HIV Granted Bail in Australia
9. Additional Radiotheraphy for Breast Cancer
10. Adding An Additional Drug May Help Patients With Glaucoma
11. Additional Responsiblities To Be Taken Up By Allied Healthcare Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... 25, 2017 , ... Lake Park Dental is now accepting new patients with ... Lutz, FL. With the help of this highly-effective, yet convenient system, patients can straighten ... discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and ...
(Date:4/25/2017)... ... 2017 , ... As Spring reignites vigilance against Zika virus-carrying ... Zika virus during pregnancy, as well as other prenatal exposures like cocaine, are ... The Teratology Society is an international and multidisciplinary group of scientists ...
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... , ... April 25, 2017 , ... There is no ... Hospital, according to a special report in the May issue of Consumer Reports focused ... highest quality ranking for results achieved during and after coronary bypass and aortic valve ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
Breaking Medicine Technology: